StockMacro
Menu

Anika Therapeutics

$13.23 -11% in 6 monthsMarket cap $177.2M

ANIK on XNAS, Health Care, Anika Therapeutics Inc, job postings

Measures activity, not value. Not investment advice.

Shares fell 36% in one month even though quarterly revenue rose 10% to $30.6M.

  • GoodRevenue for 12 months rose 9.4% to $123.4M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
235
Website
anika.com
Listed
Nasdaq, US
Last results
6 Nov 2026
Next results
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $30.6M, net loss $311K.
Quarter to 31 Dec 2021: revenue $35.8M, net income -$5.8MQuarter to 31 Dec 2021: revenue $35.8M, net income -$5.8MQuarter to 31 Mar 2022: revenue $36.7M, net income -$2.9MQuarter to 31 Mar 2022: revenue $36.7M, net income -$2.9MQuarter to 30 Jun 2022: revenue $39.7M, net income -$2.8MQuarter to 30 Jun 2022: revenue $39.7M, net income -$2.8MQuarter to 30 Sep 2022: revenue $40.3M, net income -$4.2MQuarter to 30 Sep 2022: revenue $40.3M, net income -$4.2MQuarter to 31 Dec 2022: revenue $39.6M, net income -$4.9MQuarter to 31 Dec 2022: revenue $39.6M, net income -$4.9MQuarter to 31 Mar 2023: revenue $37.9M, net income -$10.3MQuarter to 31 Mar 2023: revenue $37.9M, net income -$10.3MQuarter to 30 Jun 2023: revenue $44.3M, net income -$2.7MQuarter to 30 Jun 2023: revenue $44.3M, net income -$2.7MQuarter to 30 Sep 2023: revenue $41.5M, net income -$6.6MQuarter to 30 Sep 2023: revenue $41.5M, net income -$6.6MQuarter to 31 Dec 2023: revenue $43.0M, net income -$63.0MQuarter to 31 Dec 2023: revenue $43.0M, net income -$63.0MQuarter to 31 Mar 2024: revenue $40.5M, net income -$4.5MQuarter to 31 Mar 2024: revenue $40.5M, net income -$4.5MQuarter to 30 Jun 2024: revenue $41.9M, net income -$88KQuarter to 30 Jun 2024: revenue $41.9M, net income -$88KQuarter to 30 Sep 2024: revenue $38.8M, net income -$29.9MQuarter to 30 Sep 2024: revenue $38.8M, net income -$29.9MQuarter to 31 Dec 2024: revenue –, net income -$21.9MQuarter to 31 Mar 2025: revenue $26.2M, net income -$4.9MQuarter to 31 Mar 2025: revenue $26.2M, net income -$4.9MQuarter to 30 Jun 2025: revenue $28.2M, net income -$4.0MQuarter to 30 Jun 2025: revenue $28.2M, net income -$4.0MQuarter to 30 Sep 2025: revenue $27.8M, net income -$2.3MQuarter to 30 Sep 2025: revenue $27.8M, net income -$2.3MQuarter to 31 Dec 2025: revenue –, net income $292KQuarter to 31 Mar 2026: revenue $29.6M, net income -$5.1MQuarter to 31 Mar 2026: revenue $29.6M, net income -$5.1MQuarter to 30 Jun 2026: revenue $32.6M, net income $3.3MQuarter to 30 Jun 2026: revenue $32.6M, net income $3.3MQuarter to 30 Sep 2026: revenue $30.6M, net income -$311KQuarter to 30 Sep 2026: revenue $30.6M, net income -$311K
31 Dec 2021RevenueNet incomeNet losstallest bar $63.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$30.6M-$311K
30 Jun 2026$32.6M$3.3M
31 Mar 2026$29.6M-$5.1M
31 Dec 2025–$292K
30 Sep 2025$27.8M-$2.3M
30 Jun 2025$28.2M-$4.0M
31 Mar 2025$26.2M-$4.9M
31 Dec 2024–-$21.9M
30 Sep 2024$38.8M-$29.9M
30 Jun 2024$41.9M-$88K
31 Mar 2024$40.5M-$4.5M
31 Dec 2023$43.0M-$63.0M
30 Sep 2023$41.5M-$6.6M
30 Jun 2023$44.3M-$2.7M
31 Mar 2023$37.9M-$10.3M
31 Dec 2022$39.6M-$4.9M
30 Sep 2022$40.3M-$4.2M
30 Jun 2022$39.7M-$2.8M
31 Mar 2022$36.7M-$2.9M
31 Dec 2021$35.8M-$5.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $123.4M $112.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +9.4% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$1.8M -$33.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.13 -$2.27
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 63.4% 54.7% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -2.1% -11.0% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -1.4% -29.3% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -1.2% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $2.3M $648K
CashCash, cash equivalents and short-term investments on the latest balance sheet. $45.0M $80.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$45.0M (net cash) -$80.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $10.27
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.4 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.1 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.3 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Anika TherapeuticsANIK (this company) $177.2Mloss1.4+9.4%-1.4%
Newegg CommerceNEGG $167.8Mloss0.12+17%-0.3%
Utah Medical ProductsUTMD $198.0M18.65.7-9.6%30.5%
Pro-Dex Inc NewPDEX $201.6M16.82.5+13%15.1%
TriSalus Life SciencesTLSI $143.1Mloss3.1+15%-56.6%
ClearPoint NeuroCLPT $221.5Mloss4.9+33%-79.4%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.3%

138 13F filers vs 131

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

90%

12.1M shares held by 13F filers (30 Sep 2026) of 13.4M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.4%

324K shares sold short (30 Oct 2026) of 13.4M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.1

324K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-12%

366K shares sold short in the report before, 324K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$30.6M vs $27.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-12%

$1.7M vs $1.9M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$90K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $13.23 on 20 Nov 2026, +42% over 12 months (12-month range $9.13 to $22.03)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $264K in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, -67% on the 12 months before.
Revenue per quarter. Revenue $30.6M in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $1.7M in the latest quarter, -12% on a year earlier.
Institutional holders (13F filers). 138 13F filers reported holding it in the latest 13F quarter, +24% on a year earlier.
Lobbying spend. Lobbying spend: $90K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Oct 2026Lobbying filingnew lobbying registration (JK STRATEGIES, PUBLIC AFFAIRS ,LLC)
23 Jun 20268-K and other filingsDirector or officer change
29 Apr 20268-K and other filingsDirector or officer change
31 Mar 2026Sharp changeShort interest spike: short interest spike, 712K vs usual 403K (2026-03-13); 1.8x the same period a year earlier
17 Mar 2026Sharp changeShort interest spike: short interest spike, 732K vs usual 401K (2026-02-27); 2.0x the same period a year earlier
3 Mar 2026Sharp changeShort interest spike: short interest spike, 764K vs usual 396K (2026-02-13); 2.0x the same period a year earlier
26 Feb 20268-K and other filingsDirector or officer change
17 Feb 2026Sharp changeShort interest spike: short interest spike, 762K vs usual 391K (2026-01-30); 2.0x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 715K vs usual 391K (2026-01-15); 1.8x the same period a year earlier
13 Jan 2026Sharp changeShort interest spike: short interest spike, 583K vs usual 390K (2025-12-31); 1.5x the same period a year earlier
8 Jan 20268-K and other filingsDirector or officer change
8 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 27.8M vs usual 41.0M (2025-09-30); 0.7x the same period a year earlier
31 Jul 2025Sharp changeQuarterly revenue change: quarterly revenue change, 28.2M vs usual 41.0M (2025-06-30); 0.7x the same period a year earlier
24 Jun 20258-K and other filingsDirector or officer change
13 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, 26.2M vs usual 41.0M (2025-03-31); 0.6x the same period a year earlier
1 May 2025Sharp changeQuarterly revenue change: quarterly revenue change, -1.3M vs usual 41.0M (2024-12-31); -0.0x the same period a year earlier
10 Apr 20258-K and other filingsDirector or officer change
10 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Mar 20258-K and other filingsCompleted an acquisition or asset sale
31 Oct 20248-K and other filingsCompleted an acquisition or asset sale
28 May 20248-K and other filingsDirector or officer change
8 May 20248-K and other filingsDirector or officer change
30 Apr 2024Sharp changeShort interest spike: short interest spike, 811K vs usual 513K (2024-04-15); 1.8x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 770K vs usual 497K (2024-03-28); 1.7x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 766K vs usual 489K (2024-03-15); 1.6x the same period a year earlier
26 Feb 20248-K and other filingsDirector or officer change
26 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Nov 2023Sharp changeMany funds opening a new position: many funds opening a new position, 23 vs usual 8.50 (2023-09-30); 2.9x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 971K vs usual 521K (2023-09-15); 1.1x the same period a year earlier
21 Jun 20238-K and other filingsDirector or officer change
13 Apr 20238-K and other filingsDirector or officer change
13 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jun 20228-K and other filingsDirector or officer change
10 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Mar 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 355K)
Insider net buying (open market)
Month from 1 Mar 2022: $395K published
Month from 1 May 2022: $32K published
Month from 1 May 2026: $223K published
Month from 1 Aug 2026: $41K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $35.8M, +9.6% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $36.7M, +7.0% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $39.7M, +4.0% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $40.3M, +1.8% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $39.6M, +11% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $37.9M, +3.4% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $44.3M, +12% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $41.5M, +3.0% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $43.0M, +8.5% on a year earlier; public on 16 Mar 2024
Quarter ended 31 Mar 2024: $40.5M, +6.9% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $41.9M, -5.4% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $38.8M, -6.5% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Mar 2025: $26.2M, -35% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $28.2M, -33% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $27.8M, -28% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $29.6M, +13% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $32.6M, +16% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $30.6M, +10% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $1.1M, +151% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $1.3M, +218% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $1.9M, -16% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $1.7M, +32% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $2.5M, +124% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $1.4M, +4.8% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $1.5M, -25% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $741K, -56% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $1.8M, -27% on a year earlier; public on 16 Mar 2024
Quarter ended 31 Mar 2024: $1.8M, +30% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $3.4M, +134% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $1.2M, +64% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $1.3M, -29% on a year earlier; public on 18 Mar 2025
Quarter ended 31 Mar 2025: $2.8M, +56% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $1.5M, -57% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $1.9M, +55% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $648K, -50% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $1.4M, -49% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $1.4M, -1.2% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $1.7M, -12% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 114; public on 14 Feb 2022
31 Mar 2022 report: 110; public on 16 May 2022
30 Jun 2022 report: 119; public on 15 Aug 2022
30 Sep 2022 report: 110; public on 14 Nov 2022
31 Dec 2022 report: 111; public on 14 Feb 2023
31 Mar 2023 report: 114; public on 15 May 2023
30 Jun 2023 report: 108; public on 14 Aug 2023
30 Sep 2023 report: 108; public on 14 Nov 2023
31 Dec 2023 report: 108; public on 14 Feb 2024
31 Mar 2024 report: 114; public on 15 May 2024
30 Jun 2024 report: 107; public on 14 Aug 2024
30 Sep 2024 report: 119; public on 14 Nov 2024
31 Dec 2024 report: 108; public on 14 Feb 2025
31 Mar 2025 report: 106; public on 15 May 2025
30 Jun 2025 report: 100; public on 14 Aug 2025
30 Sep 2025 report: 111; public on 14 Nov 2025
31 Dec 2025 report: 118; public on 17 Feb 2026
31 Mar 2026 report: 126; public on 15 May 2026
30 Jun 2026 report: 131; public on 14 Aug 2026
30 Sep 2026 report: 138; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2026: $90K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $7.9M (30 Sep 2026), 1.1× its normal quarter; higher than 95% of its own history.
  • Insider net buying (open market): Insiders bought a net $264K in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months, -67% on the 12 months before.
  • Revenue per quarter: Revenue $30.6M in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 34 insider trades

No trades in the last 90 days; the latest was filed 5 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
5 Aug 2026Gary P FischettiDirectorBuy2,000$20.54$41KForm 4
4 May 2026John B Henneman IIIDirectorBuy5,000$14.66$73KForm 4
30 Apr 2026Stephen D. GriffinPresident and CEOBuy12,200$12.29$150KForm 4
12 May 2022David ColleranEVP, General Counsel, Corp SecBuy1,500$21.37$32KForm 4
16 Mar 2022David ColleranEVP, General Counsel, Corp SecBuy1,500$26.65$40KForm 4
15 Mar 2022Jeffery S ThompsonDirectorBuy2,000$24.66$49KForm 4
14 Mar 2022Michael L LevitzEVP, CFO, TreasurerBuy4,000$24.62$98KForm 4
14 Mar 2022Cheryl R BlanchardPresident, CEO, DirectorBuy8,100$25.57$207KForm 4

138 institutions reported shares at the end of Q3 2026, 90% of the shares outstanding; 18 opened a position, 12 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Caligan Partners LP1.4M10.7%$28.2MNo change
BlackRock, Inc.1.4M10.5%$27.7M-39K-2.7%
Morgan Stanley626K4.68%$12.3M+12K+2.0%
Acadian Asset Management LLC607K4.53%No change
Vanguard Capital Management LLC566K4.22%$11.1M-6,205-1.1%
Boothbay Fund Management, LLC530K3.95%$10.4M-140%
Dimensional Fund Advisors LP462K3.45%$9.1M+11K+2.4%
Renaissance Technologies LLC459K3.42%$9.0M-23K-4.7%
Geode Capital Management, LLC419K3.13%$8.2M+88K+26%
AQR Capital Management LLC401K2.99%$7.9M-159K-28%

Company events

All 53 company events

In 12 months: 4 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
14 Jul 2026Signed a major agreementSame filing: took on new debt8-K
23 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
29 Apr 2026Director or officer change8-K
26 Feb 2026Director or officer change8-K
8 Jan 2026Director or officer change8-K
24 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
10 Apr 2025Director or officer change8-K
11 Mar 2025Completed an acquisition or asset sale8-K

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Feb 2025NewJK Strategies, Public Affairs ,LLCfor Anika Therapeutics IncPromoting FDA prioritization of non-opioid products, Relationship-buildingHealth issuesFiling
30 Sep 2020EndedKing & Spalding LLPfor Anika Therapeutics, Inc.Not statedFiling
19 Sep 2016NewKing & Spalding LLPfor Anika Therapeutics, Inc.Health care product regulatory issuesHealth issuesFiling

The 5 newest of 61 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 20 Oct 2026Lobbying record

    ANIKA THERAPEUTICS INC: new lobbying registration (JK STRATEGIES, PUBLIC AFFAIRS ,LLC) (dated 1 Feb 2025)

  2. 6 Aug 2026Insiders record

    Fischetti Gary P (director) bought 2,000 shares of ANIK ($41,070) (dated 5 Aug 2026)

  3. 23 Jun 2026Filings record

    Director or officer change

  4. 5 May 2026Insiders record

    HENNEMAN JOHN B III (director) bought 5,000 shares of ANIK ($73,300) (dated 4 May 2026)

  5. 1 May 2026Insiders record

    Griffin Stephen D. (President and CEO) bought 12,200 shares of ANIK ($149,938) (dated 30 Apr 2026)

  6. 29 Apr 2026Filings record

    Director or officer change

  7. 25 Mar 2026Short interest and volume change

    had 712K shares sold short in the 13 Mar 2026 report, 1.8× the same report last year.

    Same report last year: 392K; its normal report is 403K.

    See the evidence
    This period
    712K (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    403K
    Typical spread (median absolute deviation)
    42K
    How far from its usual level
    +5.0
    Same report last year
    392K
    History used
    2,996 days
    2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K2026-01-15: 715K2026-01-30: 762K2026-02-13: 764K2026-02-27: 732K2026-03-13: 712K
    the 13 Mar 2026 report24 earlier reportsnormal: 403K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 11 Mar 2026Short interest and volume change

    had 732K shares sold short in the 27 Feb 2026 report, 2.0× the same report last year.

    Same report last year: 373K; its normal report is 401K.

    See the evidence
    This period
    732K (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    401K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +5.8
    Same report last year
    373K
    History used
    2,982 days
    2025-02-28: 373K2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K2026-01-15: 715K2026-01-30: 762K2026-02-13: 764K2026-02-27: 732K
    the 27 Feb 2026 report24 earlier reportsnormal: 401K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 26 Feb 2026Short interest and volume change

    had 764K shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.

    Same report last year: 380K; its normal report is 396K.

    See the evidence
    This period
    764K (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    396K
    Typical spread (median absolute deviation)
    34K
    How far from its usual level
    +7.4
    Same report last year
    380K
    History used
    2,968 days
    2025-02-14: 380K2025-02-28: 373K2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K2026-01-15: 715K2026-01-30: 762K2026-02-13: 764K
    the 13 Feb 2026 report24 earlier reportsnormal: 396K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Feb 2026Filings record

    Director or officer change

  11. 11 Feb 2026Short interest and volume change

    had 762K shares sold short in the 30 Jan 2026 report, 2.0× the same report last year.

    Same report last year: 385K; its normal report is 391K.

    See the evidence
    This period
    762K (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    391K
    Typical spread (median absolute deviation)
    28K
    How far from its usual level
    +7.4
    Same report last year
    385K
    History used
    2,954 days
    2025-01-31: 385K2025-02-14: 380K2025-02-28: 373K2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K2026-01-15: 715K2026-01-30: 762K
    the 30 Jan 2026 report24 earlier reportsnormal: 391K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 28 Jan 2026Short interest and volume change

    had 715K shares sold short in the 15 Jan 2026 report, 1.8× the same report last year.

    Same report last year: 402K; its normal report is 391K.

    See the evidence
    This period
    715K (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    391K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +6.5
    Same report last year
    402K
    History used
    2,939 days
    2025-01-15: 402K2025-01-31: 385K2025-02-14: 380K2025-02-28: 373K2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K2026-01-15: 715K
    the 15 Jan 2026 report24 earlier reportsnormal: 391K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 13 Jan 2026Short interest and volume change

    had 583K shares sold short in the 31 Dec 2025 report, 1.5× the same report last year.

    Same report last year: 390K; its normal report is 390K.

    See the evidence
    This period
    583K (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    390K
    Typical spread (median absolute deviation)
    20K
    How far from its usual level
    +3.8
    Same report last year
    390K
    History used
    2,924 days
    2024-12-31: 390K2025-01-15: 402K2025-01-31: 385K2025-02-14: 380K2025-02-28: 373K2025-03-14: 392K2025-03-31: 390K2025-04-15: 389K2025-04-30: 402K2025-05-15: 407K2025-05-30: 413K2025-06-13: 434K2025-06-30: 420K2025-07-15: 324K2025-07-31: 364K2025-08-15: 400K2025-08-29: 404K2025-09-15: 360K2025-09-30: 337K2025-10-15: 308K2025-10-31: 310K2025-11-14: 332K2025-11-28: 443K2025-12-15: 503K2025-12-31: 583K
    the 31 Dec 2025 report24 earlier reportsnormal: 390K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 8 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 8 Jan 2026Filings record

    Director or officer change

  16. 11 Nov 2025Financials change

    reported revenue of $27.8M for the quarter ended 30 Sep 2025, 28% below the same quarter last year.

    Same quarter last year: $38.8M; its normal quarter is $41.0M.

    See the evidence
    This period
    $27.8M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $41.0M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    -3.2
    Same quarter last year
    $38.8M
    History used
    5,571 days
    2023-06-30: $44.3M2023-09-30: $41.5M2023-12-31: $43.0M2024-03-31: $40.5M2024-06-30: $41.9M2024-09-30: $38.8M2025-03-31: $26.2M2025-06-30: $28.2M2025-09-30: $27.8M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $41.0M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 31 Jul 2025Financials change

    reported revenue of $28.2M for the quarter ended 30 Jun 2025, 33% below the same quarter last year.

    Same quarter last year: $41.9M; its normal quarter is $41.0M.

    See the evidence
    This period
    $28.2M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $41.0M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    -3.1
    Same quarter last year
    $41.9M
    History used
    3,378 days
    2023-06-30: $44.3M2023-09-30: $41.5M2023-12-31: $43.0M2024-03-31: $40.5M2024-06-30: $41.9M2024-09-30: $38.8M2024-12-31: $02025-03-31: $26.2M2025-06-30: $28.2M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $41.0M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 24 Jun 2025Filings record

    Director or officer change

  19. 13 May 2025Financials change

    reported revenue of $26.2M for the quarter ended 31 Mar 2025, 35% below the same quarter last year.

    Same quarter last year: $40.5M; its normal quarter is $41.0M.

    See the evidence
    This period
    $26.2M (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $41.0M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    -3.6
    Same quarter last year
    $40.5M
    History used
    5,388 days
    2022-12-31: $39.6M2023-03-31: $37.9M2023-06-30: $44.3M2023-09-30: $41.5M2023-12-31: $43.0M2024-03-31: $40.5M2024-06-30: $41.9M2024-09-30: $38.8M2025-03-31: $26.2M
    the quarter ended 31 Mar 20258 earlier quartersnormal: $41.0M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 1 May 2025Financials change

    reported revenue of -$1.3M for the quarter ended 31 Dec 2024, 103% below the same quarter last year.

    Same quarter last year: $43.0M; its normal quarter is $41.0M.

    See the evidence
    This period
    -$1.3M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $41.0M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    -10.3
    Same quarter last year
    $43.0M
    History used
    3,197 days
    2022-12-31: $39.6M2023-03-31: $37.9M2023-06-30: $44.3M2023-09-30: $41.5M2023-12-31: $43.0M2024-03-31: $40.5M2024-06-30: $41.9M2024-09-30: $38.8M2024-12-31: $0
    the quarter ended 31 Dec 20248 earlier quartersnormal: $41.0M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 10 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 10 Apr 2025Filings record

    Director or officer change

  23. 11 Mar 2025Filings record

    Completed an acquisition or asset sale

  24. 31 Oct 2024Filings record

    Completed an acquisition or asset sale

  25. 28 May 2024Filings record

    Director or officer change

  26. 8 May 2024Filings record

    Director or officer change

  27. 25 Apr 2024Short interest and volume change

    had 811K shares sold short in the 15 Apr 2024 report, 1.8× the same report last year.

    Same report last year: 461K; its normal report is 513K.

    See the evidence
    This period
    811K (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    513K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +3.6
    Same report last year
    461K
    History used
    2,299 days
    2023-04-14: 461K2023-04-28: 432K2023-05-15: 449K2023-05-31: 459K2023-06-15: 460K2023-06-30: 379K2023-07-14: 431K2023-07-31: 490K2023-08-15: 597K2023-08-31: 799K2023-09-15: 971K2023-09-29: 437K2023-10-13: 468K2023-10-31: 529K2023-11-15: 489K2023-11-30: 523K2023-12-15: 504K2023-12-29: 539K2024-01-12: 522K2024-01-31: 528K2024-02-15: 572K2024-02-29: 579K2024-03-15: 766K2024-03-28: 770K2024-04-15: 811K
    the 15 Apr 2024 report24 earlier reportsnormal: 513K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Apr 2024Short interest and volume change

    had 770K shares sold short in the 28 Mar 2024 report, 1.7× the same report last year.

    Same report last year: 463K; its normal report is 497K.

    See the evidence
    This period
    770K (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    497K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +4.6
    Same report last year
    463K
    History used
    2,281 days
    2023-03-31: 463K2023-04-14: 461K2023-04-28: 432K2023-05-15: 449K2023-05-31: 459K2023-06-15: 460K2023-06-30: 379K2023-07-14: 431K2023-07-31: 490K2023-08-15: 597K2023-08-31: 799K2023-09-15: 971K2023-09-29: 437K2023-10-13: 468K2023-10-31: 529K2023-11-15: 489K2023-11-30: 523K2023-12-15: 504K2023-12-29: 539K2024-01-12: 522K2024-01-31: 528K2024-02-15: 572K2024-02-29: 579K2024-03-15: 766K2024-03-28: 770K
    the 28 Mar 2024 report24 earlier reportsnormal: 497K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 27 Mar 2024Short interest and volume change

    had 766K shares sold short in the 15 Mar 2024 report, 1.6× the same report last year.

    Same report last year: 466K; its normal report is 489K.

    See the evidence
    This period
    766K (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    489K
    Typical spread (median absolute deviation)
    39K
    How far from its usual level
    +4.8
    Same report last year
    466K
    History used
    2,268 days
    2023-03-15: 466K2023-03-31: 463K2023-04-14: 461K2023-04-28: 432K2023-05-15: 449K2023-05-31: 459K2023-06-15: 460K2023-06-30: 379K2023-07-14: 431K2023-07-31: 490K2023-08-15: 597K2023-08-31: 799K2023-09-15: 971K2023-09-29: 437K2023-10-13: 468K2023-10-31: 529K2023-11-15: 489K2023-11-30: 523K2023-12-15: 504K2023-12-29: 539K2024-01-12: 522K2024-01-31: 528K2024-02-15: 572K2024-02-29: 579K2024-03-15: 766K
    the 15 Mar 2024 report24 earlier reportsnormal: 489K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 26 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 26 Feb 2024Filings record

    Director or officer change

  32. 14 Nov 2023Institutional holdings change

    saw 23 13F filers open a new position in the quarter ended 30 Sep 2023, 2.9× the same quarter last year.

    Same quarter last year: 8; its normal quarter is 8.5.

    See the evidence
    This period
    23 (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    8.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +3.9
    Same quarter last year
    8
    History used
    3,652 days
    2021-09-30: 52021-12-31: 52022-03-31: 82022-06-30: 202022-09-30: 82022-12-31: 132023-03-31: 92023-06-30: 102023-09-30: 23
    the quarter ended 30 Sep 20238 earlier quartersnormal: 8.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 27 Sep 2023Short interest and volume change

    had 971K shares sold short in the 15 Sep 2023 report, 1.1× the same report last year.

    Same report last year: 917K; its normal report is 521K.

    See the evidence
    This period
    971K (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    521K
    Typical spread (median absolute deviation)
    74K
    How far from its usual level
    +4.1
    Same report last year
    917K
    History used
    2,086 days
    2022-09-15: 917K2022-09-30: 990K2022-10-14: 995K2022-10-31: 987K2022-11-15: 957K2022-11-30: 847K2022-12-15: 586K2022-12-30: 656K2023-01-13: 543K2023-01-31: 504K2023-02-15: 512K2023-02-28: 529K2023-03-15: 466K2023-03-31: 463K2023-04-14: 461K2023-04-28: 432K2023-05-15: 449K2023-05-31: 459K2023-06-15: 460K2023-06-30: 379K2023-07-14: 431K2023-07-31: 490K2023-08-15: 597K2023-08-31: 799K2023-09-15: 971K
    the 15 Sep 2023 report24 earlier reportsnormal: 521K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 21 Jun 2023Filings record

    Director or officer change

  35. 13 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 13 Apr 2023Filings record

    Director or officer change

  37. 10 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 10 Jun 2022Filings record

    Director or officer change

  39. 13 May 2022Insiders record

    Colleran David (EVP, General Counsel, Corp Sec) bought 1,500 shares of ANIK ($32,055) (dated 12 May 2022)

  40. 17 Mar 2022Insiders record

    Colleran David (EVP, General Counsel, Corp Sec) bought 1,500 shares of ANIK ($39,975) (dated 16 Mar 2022)

Showing the newest 40 of 85 entries; narrow the window or the kind of data to see older ones.

Not listed: 135 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000898437
Ticker
ANIK
Domain
anika.com
Employer name
Anika Therapeutics, Inc. (1 unverified)
Hq location
MA|BEDFORD|01730 (1 unverified)
Lobbying client
anika therapeutics
Name
ANIKA RESEARCH INC, Anika Securities, Inc, Anika Therapeutics Inc
Uei
SGFCZAHDM7N7
  • DOL H-1B labor condition applications and PERM certifications54 data points12 Oct 2020 to 19 Jan 2026
  • Federal lobbying disclosures (LDA)3 records, 44 data points19 Sep 2016 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)155 records6 Jan 2016 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1146 data points31 Dec 2008 to 30 Oct 2026
  • SEC Form 4 insider transactions34 records, 128 data points29 Feb 2016 to 5 Aug 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards18 data points13 Dec 2012 to 8 Jun 2021